(redirected from Growth hormone deficiency)
Also found in: Medical, Wikipedia.
GHDGrowth Hormone Deficiency
GHDGood Hair Day
GHDGlobal Handwashing Day (October 15)
GHDGroundhog Day
GHDGood Humanitarian Donorship
GHDGlucose Dehydrogenase (enzyme)
GHDGutteridge Haskins and Davey
GHDGraduate Hall Director (university housing)
GHDGonadal Hyper Distension (fitness training device)
GHDGround Hound Detection Services, Inc. (Boynton Beach, FL)
GHDGrowth Hormone Disorder
GHDGlobal Help Desk
GHDGlute Hamstring Developer (Ballistix Fitness; South Africa)
References in periodicals archive ?
(3.) Donadieu J, Rolon MA, Thomas C, Doz F, Barkaoui M et al Incidence of growth hormone deficiency in pediatric-onset Langerhans cell histiocytosis: efficacy and safety of growth hormone treatment.
Responses of the tests in the subjects with and without GHD ITT L-dopa Responsive No responsive Responsive No responsive GHD (+) 2 21 1 16 GHD (-) 13 7 10 5 Clonidine Glucagon Responsive No responsive Responsive No responsive GHD (+) 3 8 0 10 GHD (-) 9 1 2 0 ITT: insulin tolerance test; GHD: growth hormone deficiency Table 5.
The guidelines are based on 166 published studies examining the prevalence and diagnosis of growth hormone deficiency in adults, as well as treatment strategies and their long-term risks and benefits, said Dr.
Initially commercialized by US Eli Lilly in 1987, Humatrope is currently approved for the treatment of adult growth hormone deficiency in more than 60 countries worldwide.
The company serves patients with chronic diseases such as Hemophilia, Multiple Sclerosis, Growth Hormone Deficiency, Respiratory Syncytial Virus, Crohn's Disease, Hepatitis-C, HIV/AIDS, Primary and Severe Combined Immunodeficiency and Cancer.
These biologicals are used to treat anemias, neutropenia, growth hormone deficiency, diabetes, and acute myocardial infarction, respectively.
Ascendis Pharma announced positive top-line results from the phase 3 heiGHt Trial, a randomized, open-label, active-controlled trial that compared once-weekly TransCon Growth Hormone to a daily growth hormone in children with pediatric growth hormone deficiency. The trial met its primary objective, demonstrating that TransCon hGH was observed to be non-inferior and, additionally, superior to the daily hGH on the primary endpoint of annualized height velocity at 52 weeks.
Macrilen (macimorelin) has been granted orphan drug designation by the FDA for the evaluation of growth hormone deficiency. On December 20, 2017, the FDA granted Aeterna Zentaris marketing approval for Macrilen (macimorelin) to be used in the diagnosis of patients with adult growth hormone deficiency (AGHD).
Here, we report a case of WBS associated with growth hormone deficiency (GHD).
According to the company, hGH-CTP is a novel, long-acting recombinant human growth hormone analog being developed for the treatment of children with growth failure due to inadequate endogenous growth hormone secretion, and adults with growth hormone deficiency (GHD) of either childhood or adult-onset etiology.
Research shows that growth hormone deficiency has been identified in approximately 1 in every 3,800 children.
Implications of a data-driven approach to treatment with growth hormone in children with growth hormone deficiency and Turner syndrome.
Full browser ?